Le Lézard
Classified in: Ebola virus, Health

Einstein Receives $178 Million in NIH Funding in Fiscal Year 2019, Largest Annual Total in Institution's History


BRONX, N.Y., Dec. 10, 2019 /PRNewswire/ -- Researchers at Albert Einstein College of Medicine secured $178 million from the National Institutes of Health in federal fiscal year 2019, marking the largest annual total in the institution's history (excluding supplemental stimulus funding distributed as a part of the American Recovery and Reinvestment Act of 2009). Major grants included those to lead international consortiums to study Ebola and HIV, as well as those focusing on neuroscience, genetics, and improving health among minority groups. 

Albert Einstein College of Medicine Logo. (PRNewsFoto/Albert Einstein College of Medicine)

"Despite an increasingly competitive environment, our researchers have reached new heights this year, clearly demonstrating their leadership and excellence across a wide range of fields," said Gordon F. Tomaselli, M.D., the Marilyn and Stanley M. Katz Dean at Einstein. "Whether using the latest technology to untangle complex biological puzzles or tailoring care to minority populations to reduce health disparities, our faculty continues to advance scientific knowledge and improve the health of our borough, our country, and our world."

Among the year's notable grants are those in which Einstein faculty lead major, national projects and centers:

Among the new major grants for investigator-initiated research projects are:

About Albert Einstein College of Medicine

Albert Einstein College of Medicine is one of the nation's premier centers for research, medical education and clinical investigation. During the 2019-20 academic year, Einstein is home to 724 M.D. students, 158 Ph.D. students, 106 students in the combined M.D./Ph.D. program, and 265 postdoctoral research fellows. The College of Medicine has more than 1,800 full-time faculty members located on the main campus and at its clinical affiliates. In 2019, Einstein received more than $178 million in awards from the National Institutes of Health (NIH). This includes the funding of major research centers at Einstein in aging, intellectual development disorders, diabetes, cancer, clinical and translational research, liver disease, and AIDS. Other areas where the College of Medicine is concentrating its efforts include developmental brain research, neuroscience, cardiac disease, and initiatives to reduce and eliminate ethnic and racial health disparities. Its partnership with Montefiore, the University Hospital and academic medical center for Einstein, advances clinical and translational research to accelerate the pace at which new discoveries become the treatments and therapies that benefit patients. Einstein runs one of the largest residency and fellowship training programs in the medical and dental professions in the United States through Montefiore and an affiliation network involving hospitals and medical centers in the Bronx, Brooklyn and on Long Island. For more information, please visit www.einstein.yu.edu, read our blog, follow us on Twitter, like us on Facebook, and view us on YouTube.

SOURCE Albert Einstein College of Medicine


These press releases may also interest you

at 07:46
viRepel Inc. (www.viRepel.ca) today announced the results of a landmark laboratory study showing conclusive evidence that its flagship product ? viRepel AC ? possesses significant antiviral properties that kill the Coronavirus (SARS-CoV-2)....

at 07:44
Aegle Therapeutics Corporation today announced  the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to AGLE-102tm for the treatment of patients with dystrophic epidermolysis bullosa ("DEB"), a rare genetic pediatric skin...

at 07:35
Pulse Biosciences, Inc. , a novel bioelectric medicine company progressing Nano-Pulse Stimulationtm (NPStm) technology, today announced FDA Investigational Device Exemption (IDE) approval and initiation of a pivotal study to evaluate the treatment of...

at 07:35
WELL Health Technologies Corp. ("WELL" or the "Company") is pleased to announce that it has entered into an agreement pursuant to which Eight Capital and Stifel GMP, as co-lead underwriters and joint bookrunners, together with a syndicate of...

at 07:35
Auxly Founder & Chair Chuck Rifici has resigned from the Board of Directors; independent director Genevieve Young appointed new Chair, effective immediatelyNew independent director Vikram Bawa to join the Board, bringing extensive senior global...

at 07:35
The Empire Life Insurance Company (Empire Life) is adding telemedicine services to its Voyageur Global Benefits suite of expatriate benefit plans administered by MetLife, effective October 1, 2020. This new service increases safety and convenience...



News published on 10 december 2019 at 15:03 and distributed by: